March 24, 2026

GLP-1 RAs Linked to Vision Risks

What the data reveal — and what remains dangerously unresolved — as millions of patients start these drugs indefinitely.

Conexiant

March 24, 2026

Review Supports Fluids, Diet to Prevent Recurrent Kidney Stones

A systematic review found low-strength evidence that increased fluid intake, a calcium-normal/higher, lower-protein, lower-sodium diet, and some drug therapies may reduce recurrent calcium stone events in adults; evidence was limited in children and absent for surveillance imaging.

Conexiant

March 20, 2026

Obesity Care Lags Behind Advances in Treatment

A 2026 expert perspective highlights system-level gaps in care delivery

Conexiant

March 20, 2026

FDA Clears Setmelanotide for Hypothalamic Obesity

First and only FDA-approved therapy showed an 18.4% placebo-adjusted BMI reduction at 52 weeks

Conexiant

March 20, 2026

Healthy Lifestyle Lowers Cardiometabolic Risk in Hypertension

Sustained and improved behaviors following diagnosis tied to lower cardiometabolic risk, highlighting an underused opportunity in care

Conexiant

March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant

March 19, 2026

Sleeve vs Gastric Bypass: Nutrient Intake at 1 Year

Investigators analyze 4-day food records and supplement reports from 285 patients at seven Swedish metabolic and bariatric centers in a substudy of the randomized BEST trial.

Conexiant

March 19, 2026

Wearable Trackers: These Activity Metrics Drive Calorie Burn

Machine learning model shows intensity and distance—not light activity—shape energy expenditure.

Conexiant

March 18, 2026

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

Conexiant

March 18, 2026

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

Conexiant